KYODO NEWS IMAGELINK

報道写真の購入なら共同通信イメージズ

  • 新型肺炎
  • チェック
  • レベル
  • 放射線
  • 放射能
  • 日本
  • 清州市
  • 記者
  • じゅんいちろう
  • スーパーマーケットチェーン

「医薬品安全」の写真・グラフィックス・映像

絞り込み
  • 提供元
  • 日付
  • 種類
  • 向き
  • カテゴリ
並び順
  • 古い順
30
( 1 30 件を表示)
  • 1
30
( 1 30 件を表示)
絞り込み
並び順
  • 古い順
  • 1996年11月29日
    厚相に最終報告書 臨床試験費用は医療機関に

    小泉純一郎厚相(右)に最終報告書を渡す医薬品安全性確保対策検討会の森亘座長=29日午後、厚生省(こいずみ・じゅんいちろう)(もり・わたる)

    商品コード: 1996112900066

  • 本画像はログイン後にご覧いただけます
    2013年09月16日
    水産庁増殖推進部長 韓国に輸入規制撤回要求

    水産物の輸入規制撤回を求め、韓国の食品医薬品安全庁を訪れた水産庁の香川謙二増殖推進部長(中央)=16日、韓国中部五松(共同)

    商品コード: 2013091600332

  • 本画像はログイン後にご覧いただけます
    2013年09月16日
    協議する日韓 韓国に輸入規制撤回要求

    韓国の食品医薬品安全庁を訪れ、韓国側(左)と協議する水産庁の香川謙二増殖推進部長(右手前)=16日、韓国中部五松(共同)

    商品コード: 2013091600372

  • 2014年04月13日
    Man leaves drugstore in Beijing

    February 5, 2009, BEIJING, CHINA: A Chinese man leaves a drugstore in downtown Beijing February 05, 2009. China is battling a string of food and drug safety scandals and has vowed to get tough, and the government has warned that the economic slowdown could lead to more cases as struggling drug makers cut corners and violate standards. (Credit Image: © Stephen Shaver/ZUMA Press Wire)、クレジット:©Stephen Shaver/ZUMA Press Wire/共同通信イメージズ

    商品コード: 2022030509858

  • 2019年06月02日
    韓国食品医薬品安全庁 対象外なのに「韓国認可」

    韓国食品医薬品安全庁が入る建物=4月、韓国・清州市(共同)

    商品コード: 2019060201545

  • 2019年06月02日
    取材に応じる金達煥報道官 対象外なのに「韓国認可」

    取材に応じる韓国食品医薬品安全庁の金達煥報道官=4月、韓国・清州市(共同)

    商品コード: 2019060201555

  • 本画像はログイン後にご覧いただけます
    2019年08月21日
    会見する李氏 放射性物質検査を強化

    記者会見する韓国食品医薬品安全庁の李丞鎔・輸入食品安全政策局長=21日、ソウル(共同)

    商品コード: 2019082100319

  • 2020年02月24日
    Emergency mask supply Emergency mask supply

    Emergency mask supply This photo, provided by the food and drug safety ministry, shows boxes containing 1 million masks that the ministry is supplying to residents of Daegu and Cheongdo in the southeast of South Korea as the coronavirus-hit areas were designated as “special care zones.“ (PHOTO NOT FOR SALE) (Yonhap)/2020-02-24 17:14:20/ < 1980-2020 YONHAPNEWS AGENCY. .> (Newscom TagID: yonphotos163596.jpg) [Photo via Newscom]、クレジット:Yonhapnews/ニューズコム/共同通信イメージズ

    商品コード: 2020022705037

  • 2021年02月05日
    Final meeting on Celltrion‘s COVID-19 treatment Final meeting on Celltrion‘s COVID-19 treatment

    Final meeting on Celltrion‘s COVID-19 treatment Oh Il-whan, head of the National Institute of Food and Drug Safety Evaluation, attends a final meeting on the conditional approval of Celltrion Inc.‘s CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, at the food and drug safety ministry in Cheongju, North Chungcheong Province, on Feb. 5, 2021. (Yonhap)/2021-02-05 11:35:22/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021020801043

  • 2021年02月05日
    Decisions on AstraZeneca vaccine Decisions on AstraZeneca vaccine

    Decisions on AstraZeneca vaccine Oh Il-whan (C), head of the National Institute of Food and Drug Safety Evaluation, announces the outcome of a meeting on the AstraZeneca vaccine at the food and drug safety ministry in Cheongju, North Chungcheong Province, on Feb. 5, 2021, ahead of the start of the vaccination of the whole nation later this month. It was decided at the meeting to use the vaccine in a cautious manner for people aged over 65 and to not recommend its use for pregnant women. (Yonhap)/2021-02-05 11:55:27/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021020801129

  • 2021年02月08日
    Celltrion‘s COVID-19 treatment Celltrion‘s COVID-19 treatment

    Celltrion‘s COVID-19 treatment Food and Drug Safety Minister Kim Gang-lip (R) views a sample of pharmaceutical giant Celltrion Inc.‘s COVID-19 antibody treatment, CT-P59, accompanied by the company‘s chief Seo Jung-jin, during his visit to a plant of the South Korean company in Incheon, west of Seoul, on Feb. 8, 2021. Celltrion‘s CT-P59 has won government approval on condition that it submits the results from its third clinical trial. (Yonhap)/2021-02-08 16:14:59/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021021004223

  • 2021年03月05日
    Pfizer vaccine‘s approval Pfizer vaccine‘s approval

    Pfizer vaccine‘s approval Food and Drug Safety Minister Kim Gang-lip announces the approval of the use of Pfizer‘s COVID-19 vaccine, which will be introduced under a contract between the government and the American pharmaceutical company starting at the end of the month, after a final review meeting at the ministry in Cheongju, North Chungcheong Province, on March 5, 2021. (Yonhap)/2021-03-05 15:16:21/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021030808501

  • 2021年03月29日
    Janssen COVID-19 vaccine eligible for approval: panel Janssen COVID-19 vaccine eligible for approval: panel

    Janssen COVID-19 vaccine eligible for approval: panel Kim Sang-bong, a senior officer in charge of new medicine at the food and drug safety ministry, speaks during a press conference at the ministry in Cheongju, central South Korea, on March 29, 2021, to announce the results of a panel review on the efficacy and safety of vaccines for the novel coronavirus made by Johnson & Johnson‘s Janssen. The panel said the vaccines have shown 66.9 percent efficacy, paving the way for the authorization of the country‘s third COVID-19 vaccine. (Yonhap)/2021-03-29 12:19:22/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021033109523

  • 2021年04月19日
    Checking radiation levels in fish from Japan Checking radiation levels in fish from Japan

    Checking radiation levels in fish from Japan Food and Drug Safety Minister Kim Ganglip (2nd from L) watches a researcher checking radiation levels in a fish imported from Japan in the southeastern port city of Busan on April 19, 2021. (Yonhap)/2021-04-19 16:43:04/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021042107080

  • 2021年04月19日
    Checking radiation levels in fish from Japan Checking radiation levels in fish from Japan

    Checking radiation levels in fish from Japan Researchers check radiation levels in fish imported from Japan at an office of the food and drug safety ministry in the southeastern port city of Busan on April 19, 2021. (Yonhap)/2021-04-19 16:43:32/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021042107120

  • 2021年04月23日
    COVID-19 self-testing kits COVID-19 self-testing kits

    COVID-19 self-testing kits COVID-19 self-test kits are produced at a plant of biotech firm Humasis in Gunpo, south of Seoul, on April 23, 2021. South Korea‘s drug safety agency granted conditional approval for two types of COVID-19 self-test kits, developed by two local biotech firms SD Biosensor and Humasis, as a supplementary tool to boost its testing capacity amid spiking cases. (Yonhap)/2021-04-23 16:22:24/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021042708434

  • 2021年04月23日
    COVID-19 self-testing kits COVID-19 self-testing kits

    COVID-19 self-testing kits An employee demonstrates how to use a COVID-19 self-test kit at a plant of biotech firm Humasis in Gunpo, south of Seoul, on April 23, 2021. South Korea‘s drug safety agency granted conditional approval for two types of COVID-19 self-test kits, developed by two local biotech firms SD Biosensor and Humasis, as a supplementary tool to boost its testing capacity amid spiking cases. (Yonhap)/2021-04-23 16:22:34/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021042708424

  • 2021年04月29日
    COVID-19 self-testing kits hit shelves COVID-19 self-testing kits hit shelves

    COVID-19 self-testing kits hit shelves A pharmacist shows COVID-19 self-test kits, manufactured by biotech firm SD Biosensor and distributed by Hanmi Pharmaceutical Co., at a drugstore in Seoul on April 29, 2021. South Korea‘s drug safety agency has granted conditional approval for two types of COVID-19 self-test kits, developed by local biotech firms SD Biosensor and Humasis, as a supplementary tool to boost its testing capacity amid spiking cases. (Yonhap)/2021-04-29 15:57:08/<Copyright ¨Ï 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021050709740

  • 2021年04月29日
    COVID-19 self-testing kits hit shelves COVID-19 self-testing kits hit shelves

    COVID-19 self-testing kits hit shelves A pharmacist shows COVID-19 self-test kits, manufactured by biotech firm SD Biosensor and distributed by Hanmi Pharmaceutical Co., at a drugstore in Seoul on April 29, 2021. South Korea‘s drug safety agency has granted conditional approval for two types of COVID-19 self-test kits, developed by local biotech firms SD Biosensor and Humasis, as a supplementary tool to boost its testing capacity amid spiking cases. (Yonhap)/2021-04-29 15:58:19/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021050709774

  • 2021年05月10日
    Moderna COVID-19 vaccine eligible for approval: panel Moderna COVID-19 vaccine eligible for approval: panel

    Moderna COVID-19 vaccine eligible for approval: panel Kim Sang-bong, a senior officer in charge of new medicine at the food and drug safety ministry, speaks during a press conference at the ministry in Cheongju, central South Korea, on May 10, 2021. A South Korean panel of experts said that the vaccine for the novel coronavirus by U.S. pharmaceutical company Moderna Inc. showed more than a 94 percent efficacy rate and is eligible for use, according to Kim. (Yonhap)/2021-05-10 11:37:28/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021051109265

  • 2021年05月21日
    Moderna vaccine‘s approval Moderna vaccine‘s approval

    Moderna vaccine‘s approval Food and Drug Safety Minister Kim Gang-lip announces the approval of the use of Moderna‘s COVID-19 vaccine after a final review meeting at the ministry in Cheongju, North Chungcheong Province, on May 21, 2021. (Yonhap)/2021-05-21 14:15:00/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>=クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021052410705

  • 00:39.85
    2021年05月31日
    「新華社」中国製コロナ自己検査キット、フィンランドの感染対策に貢献

    北欧フィンランドでこのほど、スーパーマーケットチェーン「リドル」が中国製新型コロナウイルス感染症自己検査キットの販売を開始した。家庭用のコロナ検査キット製品が同国で販売されるのは初めて。スーパーマーケットの責任者によると、自己検査キットの第1弾出荷分の数万箱は、全国の支店に漏れなく並べられ、現在190以上の店舗で好調な売れ行きを見せ、安定的に売れているという。この自己検査キットは、臨床検査薬・機器メーカーのアモイ波生生物技術(Boson)が製造しており、鼻腔スワブによる検体採取後、15~20分で結果が表示される。価格は30ユーロ(1ユーロ=約134円)未満となっている。フィンランドなどの欧州連合(EU)諸国では、家庭用検査キットが医療機器に分類されるため、その管理・販売は医薬品安全部門の監督管理下に置かれている。同スーパーによると、自己検査キットはEUの安全性能基準を満たすCEマークの認証を取得しているため、EU各国で販売できる。(記者/陳静) =配信日: 2021(令和3)年5月31日、クレジット:新華社/共同通信イメージズ

    商品コード: 2021053111187

  • 2021年09月13日
    Int‘l bio conference in Seoul

    Int‘l bio conference in SeoulFood and Drug Safety Minister Kim Gang-li delivers an opening address at the 2021 Global Bio Conference at a Seoul hotel on Sept. 13, 2021. (Yonhap)/2021-09-13 15:22:51/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>、クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021091415144

  • 2021年12月30日
    Antivirus biz plan for 2022

    Antivirus biz plan for 2022 Senior officials from the interior, health and food and drug safety ministries and the Korea Disease Control and Prevention Agency give a joint briefing on their business plan for 2022 to cope with the pandemic at the government complex in Sejong, central South Korea, on Dec. 30, 2021. (Yonhap)/2021-12-30 11:38:14/<Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.>、クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2021123003154

  • 2022年01月12日
    S. Korea approves Novavax COVID-19 vaccine

    S. Korea approves Novavax COVID-19 vaccine Food and Drug Safety Minister Kim Gang-lip announces the permit for the use of U.S.-based biotechnology company Novavax Inc.‘s COVID-19 vaccine during a briefing at the agency in Cheongju, around 140 kilometers south of Seoul, on Jan. 12, 2022. The protein-based vaccine, Nuvaxovid, marks the fifth COVID-19 vaccine to get approval for use in South Korea, following the ones by AstraZeneca, Pfizer Inc., Johnson & Johnson and Moderna Inc. (Yonhap)/2022-01-12 14:45:05/<Copyright ⓒ 1980-2022 YONHAPNEWS AGENCY. All rights reserved.>、クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2022011211002

  • 2022年02月09日
    Novavax‘s COVID-19 vaccine released locally

    Novavax‘s COVID-19 vaccine released locally A worker moves boxes carrying U.S.-based biotechnology company Novavax Inc.‘s COVID-19 vaccine at SK Bioscience Co. in Andong, 270 kilometers southeast of Seoul, on Feb. 9, 2022. Earlier in the day, the food and drug safety ministry allowed the domestic release of 840,000 doses of the vaccine produced by the South Korean drugmaker. (Yonhap)/2022-02-09 10:31:56/<Copyright ⓒ 1980-2022 YONHAPNEWS AGENCY. All rights reserved.>、クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2022020905511

  • 2022年02月09日
    Novavax‘s COVID-19 vaccine released locally

    Novavax‘s COVID-19 vaccine released locally Health and Welfare Minister Kwon Deok-cheol (6th from L) and other participants take part in a ceremony at SK Bioscience Co. in Andong, 270 kilometers southeast of Seoul, on Feb. 9, 2022, to mark the domestic release of U.S.-based biotechnology company Novavax Inc.‘s COVID-19 vaccine. Earlier in the day, the food and drug safety ministry allowed the domestic release of 840,000 doses of the vaccine produced by the South Korean drugmaker. (Yonhap)/2022-02-09 12:53:31/<Copyright ⓒ 1980-2022 YONHAPNEWS AGENCY. All rights reserved.>、クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2022020906152

  • 2022年02月09日
    Novavax‘s COVID-19 vaccine released locally

    Novavax‘s COVID-19 vaccine released locally Health and Welfare Minister Kwon Deok-cheol (C) attaches a seal sticker to a vehicle carrying U.S.-based biotechnology company Novavax Inc.‘s COVID-19 vaccine at SK Bioscience Co. in Andong, 270 kilometers southeast of Seoul, on Feb. 9, 2022, during a ceremony to mark the domestic release of the vaccine. Earlier in the day, the food and drug safety ministry allowed the domestic release of 840,000 doses of the vaccine produced by the South Korean drugmaker. (Yonhap)/2022-02-09 12:53:49/<Copyright ⓒ 1980-2022 YONHAPNEWS AGENCY. All rights reserved.>、クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2022020906151

  • 2022年06月27日
    S. Korea‘s COVID-19 vaccine candidate gets closer to approval

    S. Korea‘s COVID-19 vaccine candidate gets closer to approvalSeo Kyung-won, director general of the National Institute of Food and Drug Safety Evaluation, answers reporters‘ questions at the Ministry of Food and Drug Safety in Cheongju, 140 kilometers south of Seoul, on June 27, 2022, after announcing that GBP510, also known as SKYCovione, South Korea‘s first COVID-19 vaccine candidate developed by SK Bioscience, was recommended during a meeting of the ministry‘s Central Pharmaceutical Review Committee the previous day as being ready for “item approval“ in terms of its safety and efficacy. At the back is the committee‘s head Oh Il-whan. (Yonhap)/2022-06-27 11:15:48/<Copyright ⓒ 1980-2022 YONHAPNEWS AGENCY. All rights reserved.>、クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2022062705372

  • 2022年06月27日
    S. Korea‘s COVID-19 vaccine candidate gets closer to approval

    S. Korea‘s COVID-19 vaccine candidate gets closer to approval Oh Il-whan, the head of the Central Pharmaceutical Review Committee, announces the outcome of its evaluation of GBP510, South Korea‘s first COVID-19 vaccine candidate developed by SK Bioscience, at the Ministry of Food and Drug Safety in Cheongju, 140 kilometers south of Seoul, on June 27, 2022. The vaccine, also known as SKYCovione, was recommended at a meeting of the ministry‘s committee the previous day as being ready for “item approval“ in terms of its safety and efficacy, according to Oh. (Yonhap)/2022-06-27 11:16:29/<Copyright ⓒ 1980-2022 YONHAPNEWS AGENCY. All rights reserved.>、クレジット:Yonhap News Agency/共同通信イメージズ

    商品コード: 2022062705370

  • 1